IL5 and rheumatoid arthritis: However, a second steroid-sparing agent should be considered, especially in this patient with concomitant rheumatoid arthritis, such as mepolizumab, an anti-IL-5 agent, along with a disease-modifying agent to control symptoms related to the previously known articular inflammatory disease [12].